. Although the dose and duration of therapy with cyclophosphamide (cy) are known to influence the incidence of subsequent relapses in children with nephrotic syndrome, other factors which predispose to relapses after cy have not been extensively evaluated. The clinical course of 30 children with steroidsensitive, frequently-relapsing nephrotic syndrome was analyzed. Each of the pts had a renal biopsy at the time of initiation of cy, and all of the children had a complete remission while on cy (2 mg/Kg/d for 12 wks). After cy, one or more relapses occurred in 14 pts. while 16 pts had a sustained remission. There were no significant differences between the two groups of pts concerning: 1) age at onset (4.5 vs 4.9 yrs), 2) interval between onset and cy (6.35 vs 6.52 yrs), and 3) duration of follow-up after cy (4.0 vs 4.4 yrs).
for 9 to 49 days and 8 received supportive therapy only.There were no slgnlflcant differences between the 2 groups in age,sex, prevalence of extrarenal manlfestations,lowest hematocrit and platelet count ,number of transfusions needed,durat Ion of thrombo cytopenla or number of pts requiring dialysls.The treated pts were ollgurlc and requlred dialysis for a shorter period of time than the untreated pts(days with urinary output<200ml/d/day:1.6 t0.89,range 1-3 compared to 5.63f5.83,range 0-19;days between ad mlsslon and last dlalysls 2.15f2.47,range 0-6 compared to 4.8t 8.76.range 0-26) .The dtfferences however were not slgni f lcant. After periods of follw-up ranging from 3.5 to 18.25 months,all pts had gram normally and had GFR's ranging from 90 to 196ml/ nln/1.73mz. None had hamaturia.0ne of the untreated pts had mild protelnurla (7mg/ma/hr on overnight specimen).
We conclude that ASA and 0 do not alter the long t e n prognosls of HUS.The shorter duration of oligurla and of dependence on dlalysis In our treated pts,though not statlstlcally significant auggests s larger study Is warranted. 
FACTORS LIMITING GLOMERULAR FILTRATION
10 dyn-scm nl/(s!nnHg Imm. 47f1 16fl 31+1 26f2 79f5 .33f.01 7fl 6f0 >.040+.00? Ad. 48fl 14f0t 34f0t 40fzt 131f11t .31f .O1 2f0t 2?0* >.093?.005
Thus, mean values for PGc, PT and SNFF in immature were essen tially the same as those in adult. Since the net force for ultrafiltration at the efferent end of the glomerular capillary network (given by PGC-P~-II~) was essentially zero in immature an adult alike. Kf was not a factor limiting SNGFR in either group. Instead, the lower values for SNGFR per gram kidney weight (KW) in immature than adult are primarily a consequence of lower QA/ gKW, the latter due, at least in part, to markedly higher RA and RE. The causes for these higher resistances, whether structural or humoral, remains to be determined. Cefazolin has not been studied before in children with renal insufficiency. A single dose of 7 mq/kg was administered to 10 children (14-16 yr) with varying degrees of renal impairment (Grp I), and to 10 children 17-11 yr) undergoing hemdialysis (Grp II). Serum half-life (T/2) in hours was calculated from disappearance curves and creatinine clearance was obtained ( had less prolongation of T/2 than did the children. The drug d% not alter the tubular reabsorption of phosphate or the clearance of uric acid. In Grp I1 the T/2 was 8.25-29.5 hrs. A value of 6.5 hrs. has been reported for adults. The T/2 increased as the efficiency of dialysis, estimated by per cent reduction of BUN and creatinine, fell. T/2 of cefawlin is prolonged in children with renal insufficiency and the degree of prolongation is comparable to adults when the CICris only mderately reduced. As the CICr falls further, the T/2 increases m r e a m n g the children.
T/2 for children on hemdialysis varies with the efficiency of dialysis. Supported in part by NIH grants RR-75 and RR-5624. The antihypertensive agent clonidine (C) appears to lower blood pressure (BP) via central alpha-adrenergic stimulation. In order to determine safety and efficacy of this drug, an openlabel study was done in 16 hypertensive children and adolescents (ages 7-18). C (.15 to l.lmg/day) was used when other agents ha failed or were medically undesirable; informed consent was obtained. 8 patients (P) had post-transplant hypertension; 6, chronic nephritides, 1, polycystic-hamartomatous kidneys; and 1, essential hypertension. 10 of 16 P had BP controlled on C plus diuretic; in another 5, all with severe hypertension, C clearly improved BP control, but other agents were still required. No control was obtained in only one P (allograft renal artery disease in whom surgical repair failed). No P had hematologic or chemical abnormalities induced by the drug. Except for somnolence in 8 P, no problems occurred while regularly taking C. However, 1 of the 10 P on C plus diuretic had 2 episodes of hypertension with encephalopathy within 16 hours of drug discontinuation due to vomiting. In 2 additional patients rebound hypertension was suspected but not proven. 2 P on C plus addition a1 agents had episodes of symptomatic hypotension when C was added to their regimen. Thus C appears to be a useful and qenerally safe agent in children; however, rebound hypertension makes it important to determine patient compliance and awarenes: of the effect of vomiting episodes before the drug is prescribec .
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